Mason Carrico
Stock Analyst at Stephens & Co.
(2.96)
# 1,548
Out of 4,711 analysts
55
Total ratings
43.75%
Success rate
0.59%
Average return
Main Sectors:
Stocks Rated by Mason Carrico
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ILMN Illumina | Maintains: Overweight | $170 → $184 | $136.02 | +35.27% | 6 | Nov 12, 2024 | |
| TXG 10x Genomics | Reiterates: Overweight | $30 | $14.04 | +113.68% | 5 | Oct 10, 2024 | |
| PACB Pacific Biosciences of California | Maintains: Overweight | $3.5 → $2.5 | $1.97 | +26.90% | 2 | Aug 13, 2024 | |
| NTRA Natera | Reiterates: Overweight | $125 | $161.88 | -22.78% | 4 | Aug 9, 2024 | |
| CSTL Castle Biosciences | Reiterates: Overweight | $37 | $27.53 | +34.40% | 6 | Aug 6, 2024 | |
| HOLX Hologic | Reiterates: Overweight | $92 | $71.65 | +28.40% | 2 | Jul 30, 2024 | |
| NEO NeoGenomics | Reiterates: Overweight | $19 | $16.41 | +15.78% | 1 | Jul 30, 2024 | |
| GH Guardant Health | Reiterates: Overweight | $44 | $31.67 | +38.93% | 4 | May 24, 2024 | |
| CDNA CareDx | Maintains: Overweight | $15 → $18 | $20.61 | -12.66% | 8 | May 13, 2024 | |
| OCX OncoCyte | Reiterates: Equal-Weight | $4 | $2.19 | +82.65% | 3 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $6.32 | +42.41% | 1 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $9 | $2.49 | +261.45% | 4 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $40.89 | -16.85% | 6 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $24 | $13.36 | +79.64% | 3 | May 4, 2023 |
Illumina
Nov 12, 2024
Maintains: Overweight
Price Target: $170 → $184
Current: $136.02
Upside: +35.27%
10x Genomics
Oct 10, 2024
Reiterates: Overweight
Price Target: $30
Current: $14.04
Upside: +113.68%
Pacific Biosciences of California
Aug 13, 2024
Maintains: Overweight
Price Target: $3.5 → $2.5
Current: $1.97
Upside: +26.90%
Natera
Aug 9, 2024
Reiterates: Overweight
Price Target: $125
Current: $161.88
Upside: -22.78%
Castle Biosciences
Aug 6, 2024
Reiterates: Overweight
Price Target: $37
Current: $27.53
Upside: +34.40%
Hologic
Jul 30, 2024
Reiterates: Overweight
Price Target: $92
Current: $71.65
Upside: +28.40%
NeoGenomics
Jul 30, 2024
Reiterates: Overweight
Price Target: $19
Current: $16.41
Upside: +15.78%
Guardant Health
May 24, 2024
Reiterates: Overweight
Price Target: $44
Current: $31.67
Upside: +38.93%
CareDx
May 13, 2024
Maintains: Overweight
Price Target: $15 → $18
Current: $20.61
Upside: -12.66%
OncoCyte
Apr 17, 2024
Reiterates: Equal-Weight
Price Target: $4
Current: $2.19
Upside: +82.65%
Dec 14, 2023
Initiates: Overweight
Price Target: $9
Current: $6.32
Upside: +42.41%
Nov 13, 2023
Maintains: Overweight
Price Target: $14 → $9
Current: $2.49
Upside: +261.45%
Oct 10, 2023
Reiterates: Overweight
Price Target: $34
Current: $40.89
Upside: -16.85%
May 4, 2023
Reiterates: Equal-Weight
Price Target: $24
Current: $13.36
Upside: +79.64%